Biofrontera Inc WT (BFRIW)

$0.03 +0.00 (1.00%)
Market Cap N/A
Revenue (ttm) 34.07M
Net Income (ttm) -20.13M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 4,300
Avg Vol 8,254
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 89%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Phone: 781 245 1325
Address:
660 Main Street, 1st Floor, Woburn, United States
Latest News on BFRIW
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Mar 19, 2026, 9:25 AM EDT - 25 days ago

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Mar 9, 2026, 5:25 PM EDT - 5 weeks ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

Mar 9, 2026, 9:15 AM EDT - 5 weeks ago

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable

Feb 26, 2026, 9:15 AM EST - 6 weeks ago

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Feb 17, 2026, 9:15 AM EST - 7 weeks ago

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Feb 11, 2026, 9:15 AM EST - 2 months ago

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Feb 9, 2026, 9:15 AM EST - 2 months ago

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

Jan 13, 2026, 8:30 AM EST - 3 months ago

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Jan 8, 2026, 8:45 AM EST - 3 months ago

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

Dec 18, 2025, 8:45 AM EST - 4 months ago

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Dec 4, 2025, 9:00 AM EST - 4 months ago

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

Dec 2, 2025, 8:45 AM EST - 4 months ago

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Nov 13, 2025, 8:15 AM EST - 5 months ago

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Nov 7, 2025, 8:00 AM EST - 5 months ago

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Nov 6, 2025, 4:01 PM EST - 5 months ago

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Oct 23, 2025, 8:45 AM EDT - 6 months ago

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 26, 2025, 9:15 AM EDT - 7 months ago

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Sep 23, 2025, 9:20 AM EDT - 7 months ago

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Sep 16, 2025, 10:30 AM EDT - 7 months ago

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Aug 25, 2025, 8:25 AM EDT - 8 months ago

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 5:20 PM EDT - 8 months ago

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 11, 2025, 4:25 PM EDT - 8 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Aug 4, 2025, 2:00 PM EDT - 9 months ago

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Jun 30, 2025, 8:00 AM EDT - 10 months ago

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 11, 2025, 3:00 PM EDT - 10 months ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Jun 3, 2025, 2:30 PM EDT - 11 months ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15, 2025, 5:09 PM EDT - 11 months ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 15, 2025, 12:17 PM EDT - 11 months ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 6, 2025, 12:45 PM EDT - 1 year ago

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

May 1, 2025, 2:38 PM EDT - 1 year ago

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Mar 18, 2025, 9:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Mar 11, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Jan 8, 2025, 9:50 AM EST - 1 year ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 23, 2024, 9:30 AM EST - 1 year ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 3, 2024, 11:00 AM EST - 1 year ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 22, 2024, 9:10 AM EST - 1 year ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 13, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Nov 1, 2024, 11:55 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 31, 2024, 10:32 AM EDT - 1 year ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Oct 7, 2024, 8:45 AM EDT - 1 year ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Aug 9, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 15, 2024, 4:45 PM EDT - 2 years ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 6, 2024, 10:30 AM EDT - 2 years ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

May 3, 2024, 8:50 AM EDT - 2 years ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 26, 2024, 4:30 PM EDT - 2 years ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals